DOP2016000114A - Tratamiento de la osteoartritis y del dolor - Google Patents

Tratamiento de la osteoartritis y del dolor

Info

Publication number
DOP2016000114A
DOP2016000114A DO2016000114A DO2016000114A DOP2016000114A DO P2016000114 A DOP2016000114 A DO P2016000114A DO 2016000114 A DO2016000114 A DO 2016000114A DO 2016000114 A DO2016000114 A DO 2016000114A DO P2016000114 A DOP2016000114 A DO P2016000114A
Authority
DO
Dominican Republic
Prior art keywords
osteoarthritis
pain
treatment
Prior art date
Application number
DO2016000114A
Other languages
English (en)
Inventor
Rajesh V Kamath
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of DOP2016000114A publication Critical patent/DOP2016000114A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DO2016000114A 2011-02-08 2016-05-18 Tratamiento de la osteoartritis y del dolor DOP2016000114A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161440853P 2011-02-08 2011-02-08

Publications (1)

Publication Number Publication Date
DOP2016000114A true DOP2016000114A (es) 2016-06-15

Family

ID=46600758

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2013000178A DOP2013000178A (es) 2011-02-08 2013-08-07 Tratamiento de la osteoartritis y del dolor
DO2016000114A DOP2016000114A (es) 2011-02-08 2016-05-18 Tratamiento de la osteoartritis y del dolor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2013000178A DOP2013000178A (es) 2011-02-08 2013-08-07 Tratamiento de la osteoartritis y del dolor

Country Status (18)

Country Link
US (2) US8889130B2 (es)
EP (1) EP2672997A4 (es)
JP (2) JP5918275B2 (es)
KR (2) KR20130130825A (es)
CN (2) CN103596591B (es)
AU (2) AU2012214449B2 (es)
BR (1) BR112013020259A2 (es)
CA (1) CA2826564C (es)
CL (2) CL2013002298A1 (es)
CO (1) CO6751274A2 (es)
DO (2) DOP2013000178A (es)
IL (1) IL227771A0 (es)
MX (1) MX341578B (es)
RU (2) RU2563830C2 (es)
SG (1) SG192694A1 (es)
TW (2) TWI531377B (es)
UA (1) UA110049C2 (es)
WO (1) WO2012109373A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5903382B2 (ja) 2009-08-29 2016-04-13 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
CN105037543B (zh) 2010-03-02 2020-11-03 Abbvie 公司 治疗性dll4结合蛋白
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CN104884472B (zh) 2012-11-01 2021-10-15 艾伯维公司 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
EP3077418A2 (en) * 2013-12-02 2016-10-12 AbbVie Inc. Compositions and methods for treating osteoarthritis
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016312510A1 (en) * 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
CN105106490A (zh) * 2015-09-02 2015-12-02 济南舜昊生物科技有限公司 一种治疗小儿髋关节积液的药物及其制备方法
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
MX2018008651A (es) * 2016-01-13 2019-03-14 Merial Inc Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos.
JP2019509737A (ja) 2016-03-11 2019-04-11 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． ＴＧＦβ１結合性免疫グロブリンおよびその使用
CA3073137A1 (en) 2016-08-19 2018-02-22 Jeffrey S. Bartlett Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
ES2905227T3 (es) * 2016-10-31 2022-04-07 Kolon Life Science Inc Composición para aliviar o tratar el dolor
CN106390099A (zh) * 2016-11-07 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种牙髓干细胞组合物及其应用
EP3551650A4 (en) 2016-12-07 2020-07-08 The University of Florida Research Foundation Incorporated IL-1RA-CDNAS
CN117398457A (zh) * 2017-01-06 2024-01-16 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
TWI671761B (zh) * 2017-05-01 2019-09-11 臺中榮民總醫院 脊椎關節炎患者疾病活動度電子病歷管理系統
US11642366B2 (en) 2018-06-03 2023-05-09 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy
CN110652502A (zh) * 2018-06-28 2020-01-07 复旦大学 一种靶向治疗类风湿关节炎的药物组合物
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2286388C2 (ru) * 1988-05-27 2006-10-27 Амген Инк. Ингибитор интерлейкина-1, способ его получения, молекула днк, кодирующая ингибитор интерлейкина-1 и его предшественник
CZ299025B6 (cs) * 1996-02-09 2008-04-02 Amgen Inc. Farmaceutická kompozice a její použití
KR20080099355A (ko) * 1999-07-21 2008-11-12 오메로스 코포레이션 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
EP1481010A2 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
CA2497884C (en) * 2002-09-06 2013-10-22 Brian Varnum Therapeutic human anti-il-1r1 monoclonal antibody
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
JP2008505054A (ja) * 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
SI2314623T1 (sl) 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2618482C (en) * 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US7695718B2 (en) * 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
CA2726087A1 (en) * 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US20110165063A1 (en) 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
SG172855A1 (en) 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
BRPI1012195A2 (pt) * 2009-05-01 2018-04-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
UY32949A (es) 2009-10-15 2011-02-28 Abbott Lab Proteínas de unión a il-1
TWI615405B (zh) * 2010-05-14 2018-02-21 艾伯維有限公司 Ｉｌ-１結合蛋白
EP3674423A1 (en) 2010-07-12 2020-07-01 Gen-Probe Incorporated Compositions and assays to detect seasonal h3 influenza a virus nucleic acid
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
US20140348838A1 (en) * 2011-11-21 2014-11-27 Abbvie Inc. Il-1 binding proteins

Also Published As

Publication number Publication date
TW201527322A (zh) 2015-07-16
IL227771A0 (en) 2013-09-30
JP5918275B2 (ja) 2016-05-18
CN105749286A (zh) 2016-07-13
AU2016203917A1 (en) 2016-07-07
TW201307389A (zh) 2013-02-16
CL2016000530A1 (es) 2016-12-02
CL2013002298A1 (es) 2014-08-08
EP2672997A2 (en) 2013-12-18
NZ614207A (en) 2015-12-24
RU2015134562A3 (es) 2018-12-24
AU2012214449A1 (en) 2013-05-02
CN103596591A (zh) 2014-02-19
JP2016106086A (ja) 2016-06-16
RU2013141211A (ru) 2015-03-20
WO2012109373A2 (en) 2012-08-16
US20150050238A1 (en) 2015-02-19
CA2826564A1 (en) 2012-08-16
EP2672997A4 (en) 2015-05-06
RU2563830C2 (ru) 2015-09-20
MX341578B (es) 2016-08-25
KR20150080033A (ko) 2015-07-08
MX2013009130A (es) 2014-07-09
SG192694A1 (en) 2013-09-30
CN103596591B (zh) 2016-08-24
JP2014507434A (ja) 2014-03-27
KR20130130825A (ko) 2013-12-02
US8889130B2 (en) 2014-11-18
UA110049C2 (uk) 2015-11-10
CO6751274A2 (es) 2013-09-16
US20120201781A1 (en) 2012-08-09
AU2012214449B2 (en) 2016-07-07
RU2015134562A (ru) 2018-12-24
TWI531377B (zh) 2016-05-01
BR112013020259A2 (pt) 2018-05-15
DOP2013000178A (es) 2014-06-30
WO2012109373A3 (en) 2012-11-01
CA2826564C (en) 2018-05-15

Similar Documents

Publication Publication Date Title
DOP2016000114A (es) Tratamiento de la osteoartritis y del dolor
HK1208215A1 (en) Videographic display of real-time medical treatment
SMT201600129B (it) Trattamento della lipodistrofia
CO6930321A2 (es) Curación de tejidos
EP2968397A4 (en) DIAGNOSIS AND TREATMENT OF FIBROSIS
BR112013018469A2 (pt) dispositivos e métodos para tratamento de tecidos
EP2819703A4 (en) TREATMENT OF PAIN
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
CO6821932A2 (es) Tratamiento del dolor asociado con la dislocación de endometrio basal
GB201506561D0 (en) Treatment of amblyopia
HK1211213A1 (en) Treatment of diseases involving mucin
DK2800575T3 (da) Behandling af subarachnoidalblødning og iskæmi
DK2912186T3 (da) Behandling rettet mod blodplader
DK3060908T3 (da) Diagnosticering og behandling af autoimmune sygdomme
IL240222A0 (en) Treatment of the disease with nano-fibers of poly-n-acetylglucosamine
FR2995777B1 (fr) Methode de caracterisation des volumes de la peau
SMT201700030B (it) Capsula e dispositivo di trattamento di detta capsula
EP2670438A4 (en) SELECTION AND TREATMENT OF PATIENTS
BR112013034066A2 (pt) método de administração e tratamento
CO6990730A2 (es) Composición microbicida y proceso de obtención de la misma
HK1211778A1 (en) Ultrasound endoscope and methods of manufacture thereof
IT1392635B1 (it) Trattamento ematico di ozonoterapia
DK2916922T3 (da) Behandling af alkalisk bauxitrest
BR112013023115A2 (pt) composição de tratamento capilar
EP3104869A4 (en) Treatment of pain